PT  - JOURNAL ARTICLE
AU  - D. De Smet
AU  - K. De Smet
AU  - P. Herroelen
AU  - S. Gryspeerdt
AU  - G.A. Martens
TI  - Vitamin D deficiency as risk factor for severe COVID-19: a convergence of two pandemics
AID  - 10.1101/2020.05.01.20079376
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.01.20079376
4099  - http://medrxiv.org/content/early/2020/05/05/2020.05.01.20079376.short
4100  - http://medrxiv.org/content/early/2020/05/05/2020.05.01.20079376.full
AB  - Importance Vitamin D deficiency increases the incidence of respiratory virus infections. More than 1 billion people worldwide are vitamin D deficient. If vitamin D deficiency is associated to incidence or severity of SARS-CoV-2 infection, a global call could be made for vitamin D supplementation to mitigate the pandemic.Objective to determine if lower serum 25-hydroxyvitamin D (25(OH)D) levels are correlated to the risk for COVID-19 and its severity as measured by CTDesign single-center observational studySetting AZ Delta general hospitalParticipants 186 consecutive patients with PCR-confirmed SARS-CoV-2 infection hospitalized for COVID-19 from March 1, 2020 to April 7, 2020Main outcome and measures comparative analysis of 25(OH)D levels in patients hospitalized for COVID-19 at various radiological stages and a season/age/sex-matched diseased control populationResults we report on 186 SARS-CoV-2 infected patients requiring hospitalization for severe COVID-19: 109 males (median age 68 years, IQR 53–79 years) and 77 females (median age 71 years, IQR 65–74 years). At admission patients were screened by CT to determine temporal changes of COVID-19 lung disease and classified as stage 1 (ground glass opacities), 2 (crazy paving pattern) and 3 (consolidation). At intake, 25(OH)D levels were measured and compared to a season-matched population of 2717 diseased controls, consisting of 999 males (median age 69 years, IQR 53–81 years) and 1718 females (median age 68 years, IQR 43–83 years). Male and female COVID-19 patients combined showed lower median 25(OH)D than controls (18.6 ng/mL, IQR 12.6–25.3, versus 21.5 ng/mL, IQR 13.9–30.8; P=0.0016) and a higher fraction of vitamin D deficiency (58.6% versus 45.2%, P=0.0005). A strong sexual dimorphism was found: female patients had comparable vitamin D status as control females. Male COVID-19 patients, however, showed markedly higher percentage of vitamin D deficiency than controls (67.0% versus 49.2%, P=0.0006) and this effect was more pronounced with advanced radiological stage ranging from 55.2% in stage 1 to 74% in stage 3.Conclusions and relevance vitamin D deficiency is a possible risk factor for severe SARS-CoV-2 infection in males. Vitamin D supplementation might be an inexpensive, accessible and safe mitigation for the SARS-CoV-2 pandemic.Key pointsQuestion: does vitamin D deficiency predispose to severity of SARS-CoV-2 infection?Findings: in this observational study on 186 consecutive patients hospitalized with PCR-confirmed SARS-CoV-2 infection, we find that patients with severe COVID-19 show lower median serum 25(OH)D and a higher percentage of vitamin D deficiency at intake than a season/age-matched reference population. The correlation between vitamin D deficiency and the need for hospitalization due to COVID-19 was only seen in male patients. In males but not females, the percentage of vitamin D deficient patients also increased with more advanced COVID-19 disease stage as measured by CT.Meaning: our data indicate a strong statistical correlation between the degree of vitamin D deficiency and severity of COVID-19 lung disease. With more than 1 billion people worldwide affected by vitamin D deficiency, vitamin D supplementation might be a lifesaving, inexpensive, accessible and safe component of primary prevention during the SARS-CoV-2 pandemic and beyondCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was not funded by external or commercial sources. The costs for this study were covered by the authors and AZ Delta General Hospital.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data required for independent reproduction of our study are included in the manuscript and online supplementary files. The raw data are freely available on email request.